Roswell Park Cancer Institute (RPCI) will host a symposium titled, "Molecular Sites of Intervention for Cancer Therapeutics," October 12-13, in Buffalo, NY, to describe and discuss new approaches to the development of cancer therapeutics.
With the addition of a new procedure called uterine fibroid embolization, RPCI will expand its services to include treatment of benign fibroid tumors. UFE may preserve fertility by avoiding hysterectomy, particularly in young women with this condition.
Radio frequency ablation is being offered as a treatment option for patients with inoperable tumors by Roswell Park Cancer Institute. RFA may also be used in special cases to treat esophageal, gastrointestinal, testicular, ovarian, neuroendocrine and breast cancers.
Childhood survivors of Hodgkin's disease have a substantial risk for second malignant neoplasms, according to research published in today's Journal of Clinical Oncology.
The lessons from California's aggressive tobacco control intervention program, which has resulted in a continuing decline in adult smoking, may help to decrease adult smoking throughout the U.S., according to a study in the March American Journal of Public Health.
Roswell Park Cancer Institute Corporation has announced two administrative appointments within the Division of Head and Neck Surgical Oncology/Plastic and Reconstructive Surgery.
Amy S. Langer, Executive Director of the National Alliance of Breast Cancer Organizations, will receive the Gilda Radner Courage Award from the Roswell Park Alliance Community Fund-Raising Board at its 10th Annual All Star Night, Saturday, January 22, 2000.
Research on colorectal cancer tumors and premalignant polyps, published in the December 21 issue of the Proceedings of the National Academy of Sciences, show that cancer arises from a decade or more of cellular changes.
The first study to evaluate the impact of cardiac disease and second malignant neoplasms on late mortality and to identify risk factors for late mortality among 15-year survivors of cancer diagnosed during childhood or adolescence has concluded that survivors who relapsed during the 15-year period have excess mortality.
Roswell Park Cancer Institute is participating in a pilot study to investigate the value of magnetic resonance imaging for the detection of breast cancer in women who are at high risk for the disease. The Consortium received a $6 million National Cancer Institute grant for breast MRI clinical trials.
Roswell Park Cancer Institute scientists have found that the level of gelsolin, a protein responsible for maintaining actin filaments that are needed for healthy cells, may be of diagnostic and therapeutic value for breast cancer.
Roswell Park Cancer Institute (RPCI) and the Boyce Thompson Institute at Cornell University announced that clinical trials will begin today, Wednesday, July 7, 1999, at RPCI, to test the safety and immunogenicity of the world's first potential oral vaccine against the hepatitis B virus.
Novel genetic factors contribute to the incidence of colorectal cancer among a percentage of African-Americans, according to the results of a pioneering study conducted by a research team headed by Thomas K. Weber, MD, FACS, of the Division of Surgery, Roswell Park Cancer Institute. Their report will appear in the June 23, 1999 edition of the Journal of the American Medical Association.
Preliminary results of a pilot and a Phase II study using Rituximab to treat non-Hodgkin's lymphoma were presented at the American Society of Clinical Oncology meeting in Atlanta. These studies show Rituximab to be effective when combined with Fludarabine (a chemotherapy) and when used alone dosed in an extended eight-infusion regimen. Both trials were conducted at Roswell Park Cancer Institute and other cancer centers.
The long-term, worldwide trend of increasing breast cancer mortality rates apparently has been reversed in several countries, with significant declines reported in the United States, the United Kingdom and Canada in the 1990s. These are the findings of a study conducted at Roswell Park Cancer Institute and published in the May/June 1999 issue of CA -- A Cancer Journal for Physicians.
Researchers from Roswell Park Cancer Institute (RPCI) are part of an international group studying the long-term health effects caused by the destruction of the nuclear power plant in Chernobyl, Ukraine, April 26, 1986, which exposed thousands to radiation and contaminated farmlands in the Ukraine and Belarus.
David C. Hohn, MD, President and CEO, Roswell Park Cancer Institute (RPCI), today announced the formation of the Roswell Park Cancer Institute Corporation (RPCIC) and the composition of the RPCIC Board of Directors under the direction of Board Chairman, Mr. Patrick P. Lee, Chairman and CEO of International Motion Control Inc.
A multi-institutional clinical study led by Roswell Park Cancer Institute has demonstrated the safety and effectiveness of a chemoimmunotherapy treatment for patients with non-Hodgkin's lymphoma. The overall response rate was 95% for patients who received treatment with a combination of Rituxan, a monoclonal antibody, and the systemic standard dose chemotherapy regimen used for this disease.
A Roswell Park Cancer Institute scientist and Axis Genetics plc., Cambridge, United Kingdom, will collaborate to advance the first edible plant vaccine to protect against hepatitis B virus infection.
Fewer chemotherapy treatments, less intense side effects and fewer visits to the hospital are on the horizon for some pediatric patients. These are the results of an eight-year clinical trial in patients with Wilms' tumor, a cancer of the kidney most often seen in children, published in today's Journal of Clinical Oncology.
There is no such thing as a "safe" cigarette, concludes Roswell Park Cancer Institute (RPCI) investigators, whose comprehensive analysis of one "safe cigarette" appears in today's issue of Cancer Epidemiology, Biomarkers & Prevention.
Lung cancer is the most common cause of cancer deaths in North America. Innovative technology at RPCI will enable physicians to detect premalignant and preinvasive neoplastic lesions in the lung and initiate appropriate curative treatments such as surgery, radiation therapy, chemotherapy or in many cases, photodynamic therapy using the photosensitzer, Photofrin.
The first report of the discovery of inhaled cellulosic and plastic fibers in human lung tissue has been published by researchers at Roswell Park Cancer Institute in the May, 1998 issue of Cancer Epidemiology, Biomarkers & Prevention. The fibers in the human lung may be bioresistant and biopersistent candidate agents contributing to the risk of lung cancer.
Roswell Park Cancer Institute will host the first meeting of a Regional Cancer Center Consortium for Biological Therapy of Cancer, February 19-21, in honor of the Institute's Centennial.
The U.S. Food and Drug Administration approved the use of Photofrin(r), a light activated drug used in Photodynamic Therapy, for treatment of patients with early-stage lung cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right